Small trial targeting Epstein-Barr infections shows promise as multiple sclerosis treatment
A team of researchers at Atara Biotherapeutics has conducted a small Phase I clinical trial of a therapeutic called ATA188 that targets Epstein-Barr infections (EBV) as a treatment for multiple sclerosis (MS). Representatives ...